ESTRO 2022 - Abstract Book

S850

Abstract book

ESTRO 2022

For those interested we will provide an example excel to be used at home.

Symposium: Anal cancer

SP-0964 State of the art and future directions in primary therapy for anal cancer

D. Debag-Montefiore

UK Abstract not available

SP-0965 Definitive therapy for locally-advanced and localised metastatic anal cancer: Using the toolbox

M. Hawkins 1

1 University College London, Medical Physics and Biomedical Engineering, London, United Kingdom

Abstract Text Personalised therapy is a key objective for patients with anal cancer. We have benefited from the implementation of intensity modulated radiotherapy (IMRT), or volumetric arc therapy (VMAT), and image-guided radiotherapy (IGRT), which can deliver high doses to tumour while sparing organs at risk and thereby reducing toxicity. These now offer the possibility of investigating tailored approaches to determine the most suitable regimen in terms of radiotherapy dose prescription, target volume selection, normal tissue avoidance, and combination therapy. Radiobiological modelling of dose response and combination with classical clinicopathological parameters (T and N) has been used to propose dose escalation/de- escalation (these are tested in the ongoing PLATO trial ISRCTN 88455282). We will discuss the next steps in refining the treatment paradigms such as incorporating functional imaging to better refine biology and tumour targets and the use artificial intelligence to support selection and planning of treatment, predicting toxicity and cancer related outcomes.

SP-0966 Treating elderly and frail patients with anal cancers: What are the alternative options?

M. Guren 1

1 Oslo University Hospital, Department of Oncology, Oslo, Norway

Abstract Text The recommended treatment for patients with localized anal cancer is radiation therapy in relatively high doses delivered over several weeks with concurrent chemotherapy. However, when anal cancer occurs in patients with high age, or with significant comorbidities, or who are frail, treatment often needs to be modified. Some elderly patients are fit and are often recommended standard treatment. Others may have significant comorbidities or they may be frail. A geriatric assessment may be a useful tool for identifying frailty, and evaluating cognitive function, nutritional status, and functional impairment. This may guide treatment decisions for a modified treatment strategy or indicate supportive interventions that will increase the likelihood of completing an appropriate treatment plan. For elderly and frail patients that can not tolerate standard of care, treatment must be modified. Alternative treatment strategies are often not described in guidelines, as there is little evidence base in the literature. Clinicians often select modified treatment strategies on an individual basis and according to institutional practice. Different treatment strategies including modifications to radiotherapy and chemotherapy regimens will be discussed.

SP-0967 Biology in squamous cell carcinoma of the anus: An anal cancer or squamous cell disease?

K.Spindler

Denmark Abstract not available

Joint Symposium: ESTRO-ESR: Imaging biomarkers for personalised radiotherapy

SP-0969 The Physicist

K.R. Redalen 1

1 Norwegian University of Science and Technology, Department of Physics, Trondheim, Norway

Abstract Text Magnetic resonance imaging (MRI) and positron emission tomography (PET) are important diagnostic tools to identify location, size and stage of malignant tumors. More recently, new PET tracers and functional MRI using more advanced protocols such as diffusion-weighted MRI, dynamic contrast-based MRI and susceptibility contrast MRI allow visualization of